Therapeutic Potential of Highly Selective A

Adenosine A3 Receptor Agonists / pharmacology Arthritis, Rheumatoid / drug therapy Humans Ligands Peripheral Nervous System Receptors, Purinergic P1
A3 receptor agonists A3 receptor antagonists N-type calcium channels adenosine receptors anoxic depolarization dorsal root ganglion neurons hippocampus neurotransmission oxygen and glucose deprivation visceral pain

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
15 03 2022
Historique:
received: 31 01 2022
revised: 07 03 2022
accepted: 11 03 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 31 3 2022
Statut: epublish

Résumé

Ligands of the G

Identifiants

DOI: 10.3390/molecules27061890 PMID: 35335254 PMC: PMC8952202
pubmed: 35335254
pii: molecules27061890
doi: 10.3390/molecules27061890
pmc: PMC8952202
pii:
doi:

Substances chimiques

Adenosine A3 Receptor Agonists 0
Ligands 0
Receptors, Purinergic P1 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : University of Florence
ID : Fondi Ateneo
Organisme : Fondazione Italiana Sclerosi Multipla
ID : 2019/R-Single/036 (A.M.P.)
Organisme : Fondazione Italiana Sclerosi Multipla
ID : 2019/BS/015 (E.C.)

Références

J Physiol. 1986 Jan;370:75-90
pubmed: 2420981
Neuroscience. 2002;112(2):319-29
pubmed: 12044450
Med Res Rev. 2018 Jul;38(4):1031-1072
pubmed: 28682469
Hypertens Res. 2008 Feb;31(2):315-24
pubmed: 18360052
Neurosci Lett. 2001 Apr 13;302(1):53-7
pubmed: 11278110
Pain. 2020 Jul;161(7):1425-1441
pubmed: 32187120
Int J Oncol. 2008 Mar;32(3):527-35
pubmed: 18292929
Pain. 2018 Jun;159(6):1025-1034
pubmed: 29419652
J Med Chem. 2009 Dec 10;52(23):7897-900
pubmed: 19839592
J Neurosci. 1997 Jan 15;17(2):607-14
pubmed: 8987783
Stroke. 2008 Mar;39(3):924-8
pubmed: 18239184
Pharmacol Rev. 2020 Jan;72(1):1-49
pubmed: 31767622
Brain Behav Immun. 2015 Feb;44:91-9
pubmed: 25220279
Pharmacol Ther. 2008 Jan;117(1):123-40
pubmed: 18029023
Eur J Pharmacol. 1995 Aug 15;281(3):311-8
pubmed: 8521915
Neuroscience. 1990;38(3):757-62
pubmed: 1980146
CNS Neurosci Ther. 2019 Sep;25(9):899-910
pubmed: 31334608
Brain Behav Immun. 2018 Mar;69:470-479
pubmed: 29366930
Pflugers Arch. 2004 Feb;447(5):735-43
pubmed: 12838422
J Neurosci. 2004 Apr 7;24(14):3663-71
pubmed: 15071115
Curr Pharm Des. 2019;25(25):2697-2715
pubmed: 31333094
Turk J Pharm Sci. 2017 Apr;14(1):19-28
pubmed: 32454590
J Med Chem. 1994 Oct 14;37(21):3614-21
pubmed: 7932588
Drug Discov Today. 2012 Apr;17(7-8):359-66
pubmed: 22033198
Neuroscience. 1995 Jul;67(1):189-95
pubmed: 7477899
Pain. 2018 Jul;159(7):1325-1345
pubmed: 29561359
Eur J Pharmacol. 1994 Sep 22;263(1-2):59-67
pubmed: 7821362
J Med Chem. 2012 May 24;55(10):4847-60
pubmed: 22559880
FASEB J. 2000 Oct;14(13):2065-74
pubmed: 11023991
Front Cell Neurosci. 2019 Mar 28;13:124
pubmed: 30983976
Crit Care Nurs Clin North Am. 2016 Sep;28(3):309-16
pubmed: 27484659
Brain. 2015 Jan;138(Pt 1):28-35
pubmed: 25414036
Biomed Pharmacother. 2021 Mar;135:111164
pubmed: 33385856
Gastroenterology. 2013 Dec;145(6):1334-46.e1-11
pubmed: 23958540
Restor Neurol Neurosci. 2003;21(1-2):55-63
pubmed: 12808203
Transl Stroke Res. 2021 Oct;12(5):742-753
pubmed: 33159656
Biochem Pharmacol. 2007 Sep 1;74(5):768-79
pubmed: 17626785
Purinergic Signal. 2015 Sep;11(3):371-87
pubmed: 26111639
Pharmacol Toxicol. 1992 Jun;70(6 Pt 1):434-8
pubmed: 1438021
Anesth Analg. 2005 Nov;101(5):1417-1421
pubmed: 16244004
Pain. 2019 May;160(5):1103-1118
pubmed: 31008816
Curr Neuropharmacol. 2017;15(2):217-231
pubmed: 26861472
Trends Pharmacol Sci. 1994 Aug;15(8):298-306
pubmed: 7940998
Front Pharmacol. 2018 Apr 24;9:399
pubmed: 29740323
Curr Med Chem. 2018;25(32):3830-3865
pubmed: 28699505
J Med Chem. 2000 Jun 1;43(11):2196-203
pubmed: 10841798
Pract Neurol. 2020 Aug;20(4):304-316
pubmed: 32507747
J Cell Commun Signal. 2010 Dec;4(4):173-83
pubmed: 21234122
Eur J Pharmacol. 1984 Sep 3;104(1-2):19-26
pubmed: 6149943
Annu Rev Biomed Eng. 2009;11:135-62
pubmed: 19400711
J Med Chem. 2019 Sep 26;62(18):8511-8531
pubmed: 31453698
Purinergic Signal. 2014 Sep;10(3):465-75
pubmed: 24595664
Int J Mol Sci. 2020 Dec 18;21(24):
pubmed: 33353217
Neuroscience. 1991;44(1):131-5
pubmed: 1722888
Expert Opin Ther Targets. 2019 Aug;23(8):669-678
pubmed: 31189400
Neuropharmacology. 1997 Mar;36(3):353-62
pubmed: 9175614
J Med Chem. 2014 Dec 11;57(23):9901-14
pubmed: 25422861
Mol Neurobiol. 2009 Jun;39(3):190-208
pubmed: 19283516
Am J Gastroenterol. 2012 Nov;107(11):1702-12
pubmed: 22986437
Mol Chem Neuropathol. 1993 Jan-Feb;18(1-2):35-49
pubmed: 8096697
J Neurosci. 1998 Aug 15;18(16):6138-46
pubmed: 9698308
Epilepsy Res. 2004 Apr-May;59(2-3):83-94
pubmed: 15246113
Front Cell Neurosci. 2015 Apr 24;9:155
pubmed: 25964740
Brain Res. 2006 Feb 16;1073-1074:470-80
pubmed: 16443200
Biochim Biophys Acta. 2011 May;1808(5):1290-308
pubmed: 21185259
Brain Res Bull. 2019 Sep;151:174-180
pubmed: 31132418
Pain. 2020 Sep 1;161(9):2179-2190
pubmed: 32379223
Br J Pharmacol. 2006 Mar;147(5):524-32
pubmed: 16415905
Brain Res. 2019 Oct 1;1720:146238
pubmed: 31047885
Cell Signal. 2002 Feb;14(2):99-108
pubmed: 11781133
Nat Rev Cancer. 2013 Dec;13(12):842-57
pubmed: 24226193
J Neurophysiol. 2012 Feb;107(3):1009-21
pubmed: 22131374
Expert Opin Investig Drugs. 2000 Oct;9(10):2403-10
pubmed: 11060815
Cell Rep. 2016 Jun 28;16(1):106-119
pubmed: 27320922
Nat Rev Neurosci. 2012 Feb 22;13(4):267-78
pubmed: 22353781
Nat Rev Drug Discov. 2006 Mar;5(3):247-64
pubmed: 16518376
Br J Pharmacol. 1996 Jul;118(6):1461-8
pubmed: 8832073
Neuropharmacology. 2001;40(1):85-95
pubmed: 11077074
Nature. 2000 Jan 20;403(6767):316-21
pubmed: 10659851
Stroke. 2022 Jan;53(1):238-248
pubmed: 34802248
Pain. 2014 Dec;155(12):2560-2567
pubmed: 25242567
Mar Drugs. 2013 Mar 07;11(3):680-99
pubmed: 23470283
Neuron. 2015 Jul 15;87(2):297-309
pubmed: 26182415
Eur J Med Chem. 2012 Aug;54:470-82
pubmed: 22704999
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
Nat Neurosci. 2015 Jan;18(1):145-53
pubmed: 25420068
Eur J Pharmacol. 1996 Aug 29;310(2-3):257-61
pubmed: 8884224
ACS Med Chem Lett. 2012 Jul 12;3(7):596-601
pubmed: 23145215
Clin Exp Allergy. 1998 Aug;28 Suppl 3:35-41
pubmed: 9756184
Cell Mol Neurobiol. 2003 Jun;23(3):431-47
pubmed: 12825837
J Pharmacol Exp Ther. 1994 Feb;268(2):537-45
pubmed: 8113965
Brain Res. 1984 Mar 12;295(1):127-36
pubmed: 6324948
Pharmacol Rev. 2011 Mar;63(1):1-34
pubmed: 21303899
Biochem Pharmacol. 2020 Jul;177:113956
pubmed: 32251679
Purinergic Signal. 2020 Sep;16(3):367-377
pubmed: 32720036
Arthritis Res Ther. 2011;13(6):R197
pubmed: 22146575
J Clin Invest. 2021 Apr 1;131(7):
pubmed: 33621215
Neuroscience. 2016 Dec 3;338:1-18
pubmed: 26500181
J Biol Chem. 1993 Aug 15;268(23):16887-90
pubmed: 8349579
Lancet Neurol. 2015 Feb;14(2):162-73
pubmed: 25575710
Neuropharmacology. 2016 May;104:105-30
pubmed: 26581499
Pain. 2020 Jan;161(1):177-184
pubmed: 31490328
J Rheumatol. 2008 Jan;35(1):41-8
pubmed: 18050382
Int J Mol Sci. 2021 Aug 19;22(16):
pubmed: 34445661
Ann N Y Acad Sci. 2001 Jun;939:74-84
pubmed: 11462806
Handb Exp Pharmacol. 2009;(193):123-59
pubmed: 19639281
Curr Drug Targets. 2012 Jun;13(6):842-62
pubmed: 22250650
FASEB J. 2012 May;26(5):1855-65
pubmed: 22345405
Biochem Pharmacol. 2021 May;187:114261
pubmed: 33011161
Trends Mol Med. 2011 Apr;17(4):188-96
pubmed: 21236731
Pain Rep. 2021 Apr 02;6(1):e922
pubmed: 34585035
Pflugers Arch. 2004 Feb;447(5):728-34
pubmed: 12856181
Purinergic Signal. 2020 Dec;16(4):543-559
pubmed: 33129204
Brain Behav Immun. 2018 Mar;69:60-61
pubmed: 29499304
Expert Opin Investig Drugs. 2011 Jun;20(6):757-68
pubmed: 21457061
Physiol Rev. 2001 Jul;81(3):1065-96
pubmed: 11427692
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906

Auteurs

Elisabetta Coppi (E)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
ORCID: 0000-0003-4434-5919

Federica Cherchi (F)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
ORCID: 0000-0001-6742-456X

Martina Venturini (M)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.

Elena Lucarini (E)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
ORCID: 0000-0002-3459-2660

Renato Corradetti (R)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.

Lorenzo Di Cesare Mannelli (L)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
ORCID: 0000-0001-8374-4432

Carla Ghelardini (C)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.

Felicita Pedata (F)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.

Anna Maria Pugliese (AM)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents purinergiques › Agonistes purinergiques › Agonistes des récepteurs purinergiques P1 › Agonistes du récepteur A3 à l'adénosine › Therapeutic Potential of Highly Selective A
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Polyarthrite rhumatoïde › Therapeutic Potential of Highly Selective A
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Therapeutic Potential of Highly Selective A
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Therapeutic Potential of Highly Selective A
questionsmedicales.fr › Système nerveux › Système nerveux périphérique › Therapeutic Potential of Highly Selective A
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P1 › Therapeutic Potential of Highly Selective A